A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC

Status
Active
Cancer Type
Leukemia
Trial Phase
Phase I
Phase II
Eligibility
1 to 21, Male and Female
Study Type
Treatment
NCD ID
NCT00981799
Protocol IDs
T2008-002 (primary)
Study Sponsor
Therapeutic Advances in Childhood Leukemia Consortium

Summary

Nelarabine has shown significant activity in patients with T-cell malignancies. This study will determine the safety and maximum tolerated dose of the combination of nelarabine, cyclophosphamide and etoposide in patients with first bone marrow relapse of T-ALL, or first relapse of T-LL.

Treatment Sites in Georgia


Aflac Cancer and Blood Disorders Center of Children’s at Egleston
1405 Clifton Road NE
3rd Floor
Atlanta, GA 30322
404-785-0853
www.choa.org

Study Coordinator:
Sindy Midoro

Doctors:

Dolly Aguilera MD
Tobey J. MacDonald MD
Muna Qayed MD

Aflac Cancer and Blood Disorders Center of Children’s at Scottish Rite
5455 Meridian Mark Road
Suite 400
Atlanta, GA 30342
404-785-2215
www.choa.org

Study Coordinator:
Sindy Midoro

Doctors:

Dolly Aguilera MD
Tobey J. MacDonald MD